| 摘要: |
| 熊胆汁是自古就被用于消炎祛火的重要中药。牛磺熊去氧胆酸（tauroursodeoxycholic acid，TUDCA）为熊胆汁的主要成分，人胆汁中也有低水平的存在。为了探究TUDCA对儿童手足口病重要病原体柯萨奇病毒A16型（coxsackievirus A16， CVA16）是否有抑制作用，在病毒感染不同阶段加入TUDCA处理，通过MTT法、流式细胞术等技术检测CVA16感染的细胞存活率以及TUDCA对人横纹肌肉瘤细胞（rhabdomyosarcoma cell，RD）内吞效率的影响。结果发现，TUDCA在病毒吸附进入阶段抑制CVA16感染细胞，但不影响宿主细胞的内吞活性。研究还发现TUDCA能在病毒入侵阶段抑制水泡口炎疱疹病毒（vesicular stomatitis virus，VSV）的感染，这提示TUDCA的抗病毒作用不具有特异性。本研究发现了TUDCA抑制CVA16和VSV病毒感染这一新用途，为抗手足口病和口炎疱疹药物的研发提供了新的思路和方案。 |
| 关键词: 柯萨奇病毒A16 水泡口炎疱疹病毒 牛磺熊去氧胆酸 抗病毒药物 |
| DOI：10.14188/j.ajsh.2021.01.007 |
| 分类号:Q932 |
| 基金项目:国家自然科学基金（31070147） |
|
| Study of the inhibitory effect of Tauroursodeoxycholic acid on two kinds of virus |
|
CHEN Qian1,2, ZHU Shumin1,3, HUANG Shijia2, QU Sanfu1,3, LÜ Songya1,2
|
|
1.State Key Laboratory of Virology， Wuhan University， Wuhan 430072， Hubei， China;2.Hubei Key Laboratory of Cell Homeostasis， Wuhan University， Wuhan 430072， Hubei， China;3.China Center for Type Culture Collection， Wuhan University， Wuhan 430072， Hubei， China
|
| Abstract: |
| Bear bile has been used as an important traditional Chinese medicine to eliminate inflammation and fire since ancient times. Tauroursodeoxycholic acid （TUDCA） is the main bile acid of bear bile， and also present at low levels in human bile. To investigate whether TUDCA has an inhibitory effect on coxsackievirus A16（CVA16）， an important pathogen of children’s hand， foot and mouth disease （HFMD）， MTT method， flow cytometry and other methods were used to detect the cell survival rate of CVA16 infection under TUDCA treatment at different stages of virus infection and the effect of TUDCA on the endocytosis efficiency of RD cells. In this study， it was found that TUDCA inhibited the infection of CVA16 at the stage of virus adsorption， but did not affect the endocytosis activity of host cells. TUDCA can also inhibit the infection of vesicular stomatitis virus （VSV） in the stage of virus invasion， which suggests that TUDCA has no specific antiviral effect. The study demonstrates a new use for TUDCA to inhibit infection of HFMD virus and VSV， and provides a new way of thinking and approach for developing drugs against HFMD and VSV. |
| Key words: CVA16 VSV TUDCA antiviral drug |
